Al­lo­ri­on rais­es $50M Se­ries B; AskBio gets a new CEO

Al­lo­ri­on Ther­a­peu­tics has raised an­oth­er $50 mil­lion in a Se­ries B fi­nanc­ing round to get Phase I/II clin­i­cal tri­als in both Chi­na and the US off the ground, the on­col­o­gy and au­toim­mune dis­ease-fo­cused biotech an­nounced Thurs­day.

The biotech has raised $90 mil­lion since its be­gin­ning in 2020 with co-founders Pe­ter Ding and Fang Li. Gre­go­ry Berk has al­so joined Al­lo­ri­on as CMO to de­sign and over­see the tri­als and build out the clin­i­cal teams in the com­pa­ny’s lo­ca­tions in the US and Chi­na.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters